Letter | Published:

MEK drives BRAF activation through allosteric control of KSR proteins

Nature volume 554, pages 549553 (22 February 2018) | Download Citation


RAF family kinases have prominent roles in cancer1. Their activation is dependent on dimerization of their kinase domains, which has emerged as a hindrance for drug development2,3. In mammals, RAF family kinases include three catalytically competent enzymes (ARAF, BRAF and CRAF) and two pseudokinases (KSR1 and KSR2) that have been described as scaffolds owing to their apparent ability to bridge RAF isoforms and their substrate, mitogen-activated protein kinase kinase (MEK)4. Kinase suppressor of Ras (KSR) pseudokinases were also shown to dimerize with kinase-competent RAFs to stimulate catalysis allosterically5. Although GTP-bound RAS can modulate the dimerization of RAF isoforms by engaging their RAS-binding domains, KSR1 and KSR2 lack an RAS-binding domain and therefore the regulatory principles underlying their dimerization with other RAF family members remain unknown. Here we show that the selective heterodimerization of BRAF with KSR1 is specified by direct contacts between the amino-terminal regulatory regions of each protein, comprising in part a novel domain called BRS in BRAF and the coiled-coil-sterile α motif (CC-SAM) domain in KSR1. We also discovered that MEK binding to the kinase domain of KSR1 asymmetrically drives BRAF–KSR1 heterodimerization, resulting in the concomitant stimulation of BRAF catalytic activity towards free MEK molecules. These findings demonstrate that KSR–MEK complexes allosterically activate BRAF through the action of N-terminal regulatory region and kinase domain contacts and challenge the accepted role of KSR as a scaffold for MEK recruitment to RAF.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions


  1. 1.

    , & Alike but different: RAF paralogs and their signaling outputs. Cell 161, 967–970 (2015)

  2. 2.

    , & New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676–691 (2017)

  3. 3.

    & Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281–298 (2015)

  4. 4.

    Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6, 827–837 (2005)

  5. 5.

    , , , & A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542–545 (2009)

  6. 6.

    et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 9, 428–436 (2013)

  7. 7.

    et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366–369 (2011)

  8. 8.

    et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell 26, 402–413 (2014)

  9. 9.

    et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci USA 108, 6067–6072 (2011)

  10. 10.

    et al. A CC-SAM, for coiled coil-sterile α motif, domain targets the scaffold KSR-1 to specific sites in the plasma membrane. Sci. Signal. 5, ra94 (2012)

  11. 11.

    , , , & Complex formation between RAS and RAF and other protein kinases. Proc. Natl Acad. Sci. USA 90, 6213–6217 (1993)

  12. 12.

    , & Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205–214 (1993)

  13. 13.

    et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364, 308–313 (1993)

  14. 14.

    et al. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat. Commun. 8, 1211 (2017)

  15. 15.

    , , & Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806–819 (2010)

  16. 16.

    et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010)

  17. 17.

    et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283–1298 (2006)

  18. 18.

    et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297–7301 (1995)

  19. 19.

    et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat. Struct. Mol. Biol. 22, 37–43 (2015)

  20. 20.

    , & Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. Genetics 144, 1425–1436 (1996)

  21. 21.

    Yeast two-hybrid vectors and strains. Methods Mol. Biol. 177, 41–84 (2001)

  22. 22.

    , & Efficient random mutagenesis method with adjustable mutation frequency by use of PCR and dITP. Nucleic Acids Res. 21, 777–778 (1993)

  23. 23.

    et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235–242 (2011)

  24. 24.

    et al. ARCIMBOLDO_LITE: single-workstation implementation and use. Acta Crystallogr. D 71, 1921–1930 (2015)

  25. 25.

    & Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)

  26. 26.

    . et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010)

  27. 27.

    Acta Crystallogr. D 66, 125–132 (2010)

  28. 28.

    & HKL2MAP: a graphical user interface for macromolecular phasing with SHELX programs. J. Appl. Crystallogr. 37, 843–844 (2004)

  29. 29.

    Experimental phasing with SHELXC/D/E: combining chain tracing with density modification. Acta Crystallogr. D 66, 479–485 (2010)

  30. 30.

    et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007)

  31. 31.

    , , & Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protocols 3, 1171–1179 (2008)

  32. 32.

    et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010)

  33. 33.

    et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995)

  34. 34.

    et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005)

  35. 35.

    NMR methods for the determination of protein-ligand dissociation constants. Curr. Top. Med. Chem. 3, 39–53 (2003)

  36. 36.

    The PyMOL Molecular Graphics System, Version 1.8 (2015)

  37. 37.

    et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004)

  38. 38.

    , , , & Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189–1191 (2009)

  39. 39.

    & ALINE: a WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr. D 65, 510–512 (2009)

  40. 40.

    et al. Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions. J. Biomol. NMR 39, 275–289 (2007)

Download references


We thank L. Volpon, M. Osborne, G. Seabrook, and the Institute for Research in Immunology and Cancer High-Throughput Screening and Proteomics facilities for experimental assistance. H.L. was supported by a Canadian Institutes for Health Research (CIHR) Banting fellowship. N.T. was supported by a CIHR scholarship. Research was supported by Impact Grants from the Canadian Cancer Society (702319 to M.T. and 704116 to F.S.) and by CIHR operating grants (MOP119443 and PJT152873 to M.T. and FDN143277 to F.S.). M.T. and F.S. hold Canada Research Chairs in Intracellular Signaling and in Structural Biology of Signaling. Synchrotron work at the Northeastern Collaborative Access Team beamlines was supported by National Institutes of Health grants (P41 GM103403 and S10 RR029205).

Author information

Author notes

    • Hugo Lavoie
    • , Malha Sahmi
    •  & Pierre Maisonneuve

    These authors contributed equally to this work.


  1. Institute for Research in Immunology and Cancer Laboratory of Intracellular Signaling Université de Montréal C.P. 6128, Succursale Centre-Ville Montréal, Québec H3C 3J7, Canada.

    • Hugo Lavoie
    • , Malha Sahmi
    • , Sara A. Marullo
    • , Ting Jin
    •  & Marc Therrien
  2. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario M5G 1X5, Canada

    • Pierre Maisonneuve
    • , Neroshan Thevakumaran
    •  & Frank Sicheri
  3. Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada

    • Neroshan Thevakumaran
    •  & Frank Sicheri
  4. NE-CAT APS, Building 436E, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA

    • Igor Kurinov
  5. Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada

    • Frank Sicheri
  6. Département de pathologie et biologie cellulaire, Université de Montréal, Québec H3C 3J7, Canada

    • Marc Therrien


  1. Search for Hugo Lavoie in:

  2. Search for Malha Sahmi in:

  3. Search for Pierre Maisonneuve in:

  4. Search for Sara A. Marullo in:

  5. Search for Neroshan Thevakumaran in:

  6. Search for Ting Jin in:

  7. Search for Igor Kurinov in:

  8. Search for Frank Sicheri in:

  9. Search for Marc Therrien in:


H.L., M.S., P.M., S.A.M., F.S., and M.T. designed the experiments. H.L., P.M., F.S., and M.T. wrote the manuscript. H.L. performed BRET assays with T.J. M.S. performed co-IP and transactivation assays. H.L. and S.A.M. conducted Y2H experiments. P.M., N.T., and I.K. performed structural and biophysical experiments.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Frank Sicheri or Marc Therrien.

Reviewer Information Nature thanks D. Barford, S. Hubbard and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Life Sciences Reporting Summary

  2. 2.

    Supplementary Figure 1

    This file contains gel source data for immunoblots presented in the main and extended data figures including molecular weight markers (kDa).

Excel files

  1. 1.

    Supplementary Table 1

    The raw data of BRET-based whole-kinome screen for modulators of BRAF-KSR1 kinase domains interaction.

  2. 2.

    Supplementary Table 2

    MEK1 mutations that enable KSR1W831R-MEK1 interaction.


  1. 1.

    Conformational modification of the CC-SAM domain induced by binding of the BRS domain

    Conformational modification of the CC-SAM domain induced by binding of the BRS domain.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.